Acrivon Therapeutics Files 8-K Report

TL;DR

ACRV filed an 8-K, mostly boilerplate and exhibits, no major news yet.

AI Summary

On October 11, 2024, Acrivon Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific material events or financial figures beyond the filing date and company information were detailed in the provided text.

Why It Matters

This filing indicates Acrivon Therapeutics is making a regulatory submission to the SEC, which could contain updates on company operations or financial status, though specifics are not detailed in this excerpt.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain information that inherently increases or decreases risk.

Key Players & Entities

• Acrivon Therapeutics, Inc. (company) — Registrant
• 0000950170-24-114213 (other) — Accession Number
• 20241011 (date) — Filing Date
• 001-41551 (other) — SEC File Number
• 82-5125532 (other) — IRS Employer Identification No.
• 480 Arsenal Way Suite 100 (other) — Principal Executive Offices Address
• Watertown, Massachusetts (location) — Principal Executive Offices Location
• 02477 (other) — Principal Executive Offices ZIP Code
• (617) 207-8979 (other) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ACRV The Nasdaq Stock Mar

Filing Documents

• acrv-20241011.htm (8-K) — 41KB
• acrv-ex99_1.htm (EX-99.1) — 19KB
• img28311487_0.jpg (GRAPHIC) — 16KB
• 0000950170-24-114213.txt ( ) — 202KB
• acrv-20241011.xsd (EX-101.SCH) — 25KB
• acrv-20241011_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On October 11, 2024, Acrivon Therapeutics, Inc. (the "Company") issued a press release titled "Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single Agent Activity." A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference into this Item 7.01 of this Current Report on Form 8-K. The information set forth under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events On October 11, 2024, the Company announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ACR-2316, the Company's internally discovered, selective WEE1/PKMYT1 inhibitor, for the treatment of patients with selected solid tumors identified by AP3. The Company expects to report initial clinical data from the monotherapy Phase 1 dose optimization trial for ACR-2316 in the second half of 2025.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated October 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acrivon Therapeutics, Inc. Date: October 11, 2024 By: /s/ Peter Blume-Jensen Name: Peter Blume-Jensen, M.D., Ph.D. Title: Chief Executive Officer and President

View Full Filing

View this 8-K filing on SEC EDGAR